Immix Biopharma

IMMIX BIOPHARMA INC

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BDRX

DECK

HNRG

IMMX

INEO

INTU

LITM

LTBR

MLGO

MNSO

OKLO

ROST

SGBX

SOBR

VTAK

Why Intuit Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

AFIB

AKTS

ALPN

ALTI

AMSC

BMEA

CCTG

CISS

CMND

CNXC

COLB

CRGE

EPIX

INSG

LVTX

MRAI

ONCO

PCSA

PHUN

PROP

RDHL

RVSN

TSLA

VERA

VIRT

VSME

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance.

Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Biotech

Health Care

General

Immix Biopharma Inc (NASDAQ: IMMX) announced the presentation of updated data from the ongoing Phase 1b/2 NEXICART-1 study of its NXC-201, an autologous, BCMA-targeted chimeric antigen receptor T 

What&#39;s Going On With Cancer-Focused Immix Biopharma Stock Today?

Immix Biopharma Inc

Press Releases

Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media

Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024

Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis

Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025

Immix Biopharma to Host KOL Event to Discuss NXC-201 Clinical Data Presented at ASCO 2025 in relapsed/refractory AL Amyloidosis

Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Adicet Bio

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BeyondSpring

Celularity

Citius Oncology

Elutia

IGM Biosciences

Opus Genetics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Seres Therapeutics

Metagenomi

MediciNova

OKYO Pharma

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Skye Bioscience

Surrozen

Tenaya Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Exicure

Zura Bio Limited - Class A Ordinary shares

Zura Bio

HC Wainwright & Co.

Roth MKM

Comments

Immix Biopharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell